Remyelination is a term for the re-generation of the nerve's myelin sheath, damaged in many diseases such as multiple sclerosis (MS) and the leukodystrophies. Remyelination is a subject of active medical research.
Osteocalcin (OCN) is a multifunctional bone-derived hormone that modulates numerous physiological activities. OCN can cross the blood brain barrier (BBB) and thus play critical roles in neuronal and brain development.
In the nearly 1 million Americans living with multiple sclerosis, the fatty substance that insulates the nerves of the central nervous system—called myelin—is damaged.
Did you know multiple sclerosis (MS) means multiple scars? New research shows that the brain and spinal cord scars in people with MS may offer clues to why they developprogressive disability but those with related diseases where the immune system attacks the central nervous system do not.
A team led by a biomedical scientist at the University of California, Riverside, reports a drug -- an estrogen receptor ligand called indazole chloride (IndCl) -- has the potential to improve vision in patients with multiple sclerosis, or MS.
Seema Tiwari-Woodruff, a professor of biomedical sciences in the School of Medicine at the University of California, Riverside, and her colleagues have received a grant of $373,000 from the National Multiple Sclerosis Society for a project in which her lab will select the five best candidate compounds to speed up nerve impulses, a promising new avenue to treat multiple sclerosis.
A research team led by neurobiologist Professor Claire Jacob has identified an important mechanism that can be used to control the restoration of myelin sheaths following traumatic injury and in degenerative diseases.
Researchers from the University of Colorado School of Medicine have identified a new way that cells in the central nervous system regenerate and repair following damage.
Multiple sclerosis, characterized by increasing muscle weakness and paralysis, has a number of treatments that help stall progression of the disease when used early on in the disease.
Mohamad Khazaei, Ph.D., scientific associate in Dr. Michael Fehlings' lab at Krembil Research Institute, Toronto, is the latest recipient of STEM CELLS Translational Medicine's (SCTM) Young Investigator Award.
Measuring changes in the speed of electrical signals along nerves connecting the eyes to the brain may accurately reflect recovery from myelin loss in multiple sclerosis (MS), according to researchers at the University of Wisconsin–Madison, and could be used to evaluate new treatments for the disease.
What if the missing ‘environmental’ factor in some of our deadliest neurological diseases were really written in our genome?
Multiple sclerosis is an autoimmune disease that affects more than 2.3 million people worldwide. This debilitating condition periodically shutters communication between the brain and other parts of the body, resulting in symptoms that range from numbness and tingling in the arms and legs to blindness and paralysis.
Researchers have discovered that in adult stem cells, the activation of a specific transcription factor induces pathological quiescence and that this is deactivated in MS.
Nerve cells stripped of their insulation can no longer carry vital information, leading to the numbness, weakness and vision problems often associated with multiple sclerosis. A new study shows an overlooked source may be able to replace that lost insulation and provide a new way to treat diseases like MS.
Novartis today announced that both the US Food and Drug Administration and European Medicines Agency have accepted the company's New Drug Application and Marketing Authorization Application respectively, for investigational oral, once-daily siponimod (BAF312) for the treatment of secondary progressive multiple sclerosis in adults.
Research published today in the journal Nature provides new understanding about how drugs can repair damaged brain cells that cause disability in patients with multiple sclerosis.
For decades, clinicians treating multiple sclerosis have interpreted the appearance of new or expanding brain lesions on magnetic resonance imaging scans as a sign that a patient's disease is getting worse.
Celgene Corporation today announced that it has received a Refusal to File letter from the United States Food and Drug Administration regarding its New Drug Application for ozanimod in development for the treatment of patients with relapsing forms of multiple sclerosis.
New research suggests that administering taurine, a molecule naturally produced by human cells, could boost the effectiveness of current multiple sclerosis (MS) therapies.
Longevity Biotech, Inc. has received an award from the National Multiple Sclerosis Society through Fast Forward, the Society's commercial research funding program, to evaluate LBT-3627 in preclinical models as a potential disease-modifying therapeutic agent.